ECSP21034253A - Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina - Google Patents

Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina

Info

Publication number
ECSP21034253A
ECSP21034253A ECSENADI202134253A ECDI202134253A ECSP21034253A EC SP21034253 A ECSP21034253 A EC SP21034253A EC SENADI202134253 A ECSENADI202134253 A EC SENADI202134253A EC DI202134253 A ECDI202134253 A EC DI202134253A EC SP21034253 A ECSP21034253 A EC SP21034253A
Authority
EC
Ecuador
Prior art keywords
orexin receptor
synthetic methods
heterocyclic compounds
receptor modulators
fused heterocyclic
Prior art date
Application number
ECSENADI202134253A
Other languages
English (en)
Inventor
Luc Jozef Raphael Moens
Dinesh Gala
Andy Josephina Joannes Huygaerts
Kiran Matcha
Dominique Paul Michel Depre
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP21034253A publication Critical patent/ECSP21034253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Se describen procesos para preparar (((3aR,6aS)-5-(4,6-dimetilpirimidin-2-il)hexahidropirrolo[3,4-c]pirrol-2(1H)-il)(2-fluoro-6-(2H-1,2,3-triazol-2-il)fenil)metanona, que son útiles para la fabricación comercial. Dicho compuesto es un modulador del receptor de orexina y puede ser útil en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos y afecciones mediadas por la actividad de la orexina, tales como insomnio y depresión.
ECSENADI202134253A 2018-11-14 2021-05-14 Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina ECSP21034253A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862760995P 2018-11-14 2018-11-14

Publications (1)

Publication Number Publication Date
ECSP21034253A true ECSP21034253A (es) 2021-06-30

Family

ID=70730771

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202134253A ECSP21034253A (es) 2018-11-14 2021-05-14 Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina

Country Status (20)

Country Link
EP (1) EP3880204B1 (es)
JP (1) JP7398452B2 (es)
KR (1) KR20210091726A (es)
CN (1) CN113038952A (es)
AR (1) AR117074A1 (es)
AU (1) AU2019380072A1 (es)
BR (1) BR112021009211A2 (es)
CA (1) CA3118734A1 (es)
CR (1) CR20210240A (es)
EA (1) EA202191356A1 (es)
EC (1) ECSP21034253A (es)
IL (1) IL283067A (es)
JO (1) JOP20210110A1 (es)
MA (1) MA54250A (es)
MX (1) MX2021005698A (es)
PE (1) PE20211470A1 (es)
PH (1) PH12021551054A1 (es)
SG (1) SG11202104886YA (es)
TW (1) TW202039452A (es)
WO (1) WO2020100011A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212319A1 (en) * 2021-03-16 2022-09-22 Hualing XIAO Nitrogen-containing heterocyclic polycyclic compound, preparation method therefor, and application thereof
WO2024056016A1 (zh) * 2022-09-14 2024-03-21 江苏豪森药业集团有限公司 含氮杂环的多环化合物的自由碱晶型及其制备方法
WO2024125395A1 (zh) * 2022-12-12 2024-06-20 江苏恩华药业股份有限公司 一种取代四氢环戊基[c]吡咯衍生物、制备方法、中间体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
ZA200709626B (en) 2005-05-13 2009-02-25 Lexicon Pharmaceuticals Inc Multicyclic compounds and methods of their use
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
EP2089018A2 (en) 2006-11-07 2009-08-19 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
EP2491038B1 (en) * 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
JP5848251B2 (ja) * 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
US9938276B2 (en) * 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016171248A1 (ja) * 2015-04-24 2016-10-27 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
JP2022507361A (ja) 2022-01-18
AU2019380072A1 (en) 2021-05-27
PH12021551054A1 (en) 2021-12-06
CA3118734A1 (en) 2020-05-22
JOP20210110A1 (ar) 2023-01-30
EP3880204B1 (en) 2024-05-15
WO2020100011A1 (en) 2020-05-22
CR20210240A (es) 2021-06-08
EP3880204A1 (en) 2021-09-22
EP3880204A4 (en) 2022-08-17
JP7398452B2 (ja) 2023-12-14
MX2021005698A (es) 2021-07-07
MA54250A (fr) 2022-02-23
KR20210091726A (ko) 2021-07-22
EA202191356A1 (ru) 2021-08-11
IL283067A (en) 2021-06-30
SG11202104886YA (en) 2021-06-29
US20220009932A1 (en) 2022-01-13
PE20211470A1 (es) 2021-08-05
AR117074A1 (es) 2021-07-07
CN113038952A (zh) 2021-06-25
BR112021009211A2 (pt) 2021-08-03
TW202039452A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
ECSP21034253A (es) Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina
ECSP19047936A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
CO6541572A2 (es) Octahidropirrolo[3.4-c]pirrolos distituidos como moduladores del receptor de orexina
BR112016000195A8 (pt) compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias
SV2018005800A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
PE20211001A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CR20190282A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
CL2016001876A1 (es) Macrociclos de diarilo como moduladores de la proteína quinasa
CL2009000400A1 (es) Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
NZ722122A (en) Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
CL2011002837A1 (es) Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros.
DOP2014000039A (es) Inhibidores de pde10 de pirimidina
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
NI202000100A (es) Inhibidores de moléculas pequeñas de la familia de quinasa jak
BR112018013763A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilclona m4
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
ECSP22016630A (es) Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
PE20211638A1 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
UY36010A (es) NUEVOS COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZINA-5,8-DIONA
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases